Propofol Attenuates Brain Ischemic Injury Through the Cannabinoid Type 1 (CB1) Receptor

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• The anesthetic propofol is known to reduce ischemic brain injury, but its neuroprotective mechanisms are not fully understood.
• Propofol administration has been linked to increased endocannabinoid levels.
• Investigating the specific pathways through which propofol exerts cerebroprotection during ischemia is crucial.

Purpose of the Study:

• To investigate the cerebroprotective pathways mediated by propofol during ischemic insults.
• To determine the role of endocannabinoids and cannabinoid receptors in propofol's neuroprotective effects.

Main Methods:

• Utilized a rat middle cerebral artery occlusion (MCAO) model for in vivo studies of cerebral ischemia/reperfusion injury.
• Employed oxygen-glucose deprivation/reoxygenation (OGD/R) models in primary cultured neurons for in vitro experiments.
• Administered propofol to MCAO rats and OGD/R neurons, followed by evaluation of injury levels, apoptosis, oxidative stress, and antioxidant defenses.
• Investigated the involvement of cannabinoid type 1 (CB1) and type 2 (CB2) receptors using pharmacological blockade/antagonism.
• Measured endogenous cannabinoid levels (anandamide (AEA) and 2-arachidonoylglycerol (2-AG)) in serum.

Main Results:

• Propofol significantly reduced cerebral infarction volume, improved neurological outcomes, decreased neuronal apoptosis, and lowered oxidative stress markers in MCAO rats.
• Propofol enhanced antioxidant defenses by increasing superoxide dismutase 2 activity and glutathione production in vivo.
• In vitro, propofol preserved neuronal membrane integrity, reduced apoptotic signaling, and restored redox balance by modulating reactive oxygen species (ROS) generation.
• CB1 receptor blockade, but not CB2 antagonism, abolished propofol's protective effects in both models.
• Propofol administration increased endogenous cannabinoids (AEA and 2-AG) in the serum of ischemic subjects.

Conclusions:

• Propofol induces neuroprotection against ischemic brain injury through a mechanism involving the production of endocannabinoids (AEA and 2-AG).
• The neuroprotective effects of propofol are mediated by the cannabinoid type 1 (CB1) receptor.
• Propofol reduces oxidative stress and neuronal damage by modulating ROS generation and enhancing antioxidant levels via CB1 receptor activation.